News

Obesity and associated comorbidities strain the healthcare system, so why has R&D for new weight loss medications been lackluster?

Are you tracking your prospective pharmacy partners to measure their potential impact on your Star Rating? You should be.

Surveys conducted by the AACE with support from Sanofi US, identified differences in perceptions among adults living with type 2 diabetes. What healthcare professionals don't know may surprise you.

The standard of care for patients unable to drain their bladder is catheter use, but new alternatives reduce risk of antibiotic-resistant superbugs and costs to the healthcare system.

As the 2016 presidential election approaches, analysts and experts are advising healthcare executives to watch and monitor certain issues.

Health insurers and providers are looking for ways to grow outside of the United States. Here’s a look at some of the tactics that are picking up traction.

FDA added new safety labeling changes for a class of antibiotics, fluoroquinolones (Levaquin, Cipro and other branded drugs), to enhance warnings about their association with disabling and potentially permanent side effects. Plus, the new labeling says that the drugs’ use should be limited in patients with less serious bacterial infections.

FDA approved lixisenatide (Adlyxin, Sanofi-Aventis), a once-daily mealtime GLP-1 receptor agonist injection for type 2 diabetes, which will compete against the once-weekly pen dulaglutide (Trulicity, Eli Lilly) and the injectable liraglutide (Victoza, Novo Nordisk).

Mayo Clinic researchers found that beyond overtesting, focus on HbA1C levels can lead to serious harms for patients, especially as more diabetes drugs are needed to keep HbA1C within desired targets.

Obesity affects almost 38% of U.S. adults, according to the CDC’s National Health and Nutrition Examination Survey. Here’s how plans and providers can create positive change.

The Medicare Star Ratings program is one way regulators are trying to improve outcomes while reducing costs, but what is really at stake for health plans, and do consumers even care?

Given what will occur in California, what should executives be aware of? What does the future hold for exchanges nationwide? Experts weigh in.

GAO report raises questions about programs for Medicare/Medicaid beneficiaries, but industry insiders remain optimistic.

To participate in Medicare and Medicaid, hospital and critical access hospitals (CAHs) would need to meet new criteria.

Michael Abrams of Numerof and Associates healthcare consulting firm discusses how the DOJ’s actions to block the Anthem-Cigna and Aetna-Humana mergers could affect the industry.

The government recently filed lawsuits to block Aetna-Humana and Anthem-Cigna mergers. Here’s how experts say this will impact the industry.

Several lawsuits have been filed by qualified health plans offering coverage on the Affordable Care Act health insurance exchanges.

Losing weight requires dramatic behavioral and lifestyle changes. Here’s how physicians can get patients on board.

FDA recently approved the New Drug Application (NDA) for (lorcaserin HCl) CIV extended-release 20 mg tablets (Belviq XR, Eisai Inc. and Arena Pharmaceuticals), a once-a day dosing option for chronic weight management.

FDA recently approved an expansion to the prescribing information for darunavir (Prezista, Janssen Therapeutics), to treat pregnant women with HIV.

A new “secret shopper” study shows that problems exist for patients with acute conditions accessing services for patients. Effectively addressing issues of network adequacy may require more accurate provider information.

The Managed Healthcare Executive editorial advisory board says healthcare executives should watch out for these seven leadership deficiencies.

Medication nonadherence and complications from type 2 diabetes is resulting in signficant economic and societal burdens in the U.S. and other countries, according to a new report.

President Obama recently reviewed the ACA. Find out what he said are the top successes, and how policy insiders are reacting.

Clinton and Trump are keeping mum about some healthcare issues, and that’s raising some critical questions. Managed Healthcare Executive asked industry experts to comment on what topics presidential candidates are being quiet about, and why they suspect they’re not talking about them.

A new survey from Willis Towers Watson has interesting findings related to how employers view exchange viability

Shifting patient demographics will create an ideal scenario for the online/mail-order pharmacy market in the next five to ten years.

The impacts of the ever-changing health care marketplace and how employers, brokers and carriers have adapted